Fundamentals data is not available for this company.
Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 334.95 | 3.69 | (37.28)¢ | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-26 | 390.46 | 60.69 | 41.33¢ | 23.4 | n/a | n/a | n/a | 0.0% |
31-Dec-27 | 450.61 | 74.79 | 59.93¢ | 16.2 | 0.4 | +45% | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
No recent information was found.
Dynavax, Merck team up on hepatitis B vaccine | 02-Nov-2007 | BayArea.com |
Merck Buys License to Sell New Vaccine for Hepat... | 01-Nov-2007 | New York Times |
Business Digest | 20-Jan-2006 | BayArea.com |
Currency | US Dollars |
Share Price | $ 9.69 |
Change Today | $ -0.06 |
% Change | -0.62 % |
52 Week High | $14.40 |
52 Week Low | $9.36 |
Volume | 5,633,420 |
Shares Issued | 65.06m |
Market Cap | $630.47m |
RiskGrade | 699 |
Strong Buy | 1 |
Buy | 4 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 6 |
Time | Volume / Share Price |
16:00 | 3,125,661 @ $9.69 |
15:59 | 200 @ $9.69 |
15:59 | 41,071 @ $9.68 |
15:59 | 200 @ $9.69 |
15:59 | 100 @ $9.69 |
You are here: research